EURECCA Activity Report, November 2018

Transcription

1 EURECCA Activity Report, November 2018 Update on EURECCA s projects and activities of the past years and future plans.

2 Index Introduction EURECCA. Page 3, 4 EURECCA Colorectal Page 5-7 EURECCA Upper GI.. Page 8, 9 EURECCA Pancreas... Page 10 EURECCA Breast... Page 11 EURECCA Melanoma. Page 12 2 P age

3 Introduction EURECCA (acronym for EUropean REgistry of Cancer CAre or EURopEan CanCer Audit), started in 2007 as an ECCO/ESSO initiative. EURECCA is an international multidisciplinary platform of clinicians and epidemiologists aiming to improve the quality of cancer care by data registration, feedback, forming plans for improvement and sharing knowledge of performance and science. EURECCA is registered as a foundation, based in Leiden. Relevant background: Still considerable variation exists in Europe in cancer management and outcome. Moreover, there is an urgent need for transparent uniform international data collection and analysis, in order to monitor and learn from all aspects of cancer care and to provide feedback and education. Uniform datasets are necessary, not existent yet. The strategic plan of EURECCA was written in 2013 to professionalize EURECCA in the next 6 years ( ). The vision - EURECCA will become the trademark for quality assurance in cancer management in Europe, and provide a dedicated infrastructure to audit patient outcome, monitor standardized cancer care and assure equal access for cancer patients to high quality care in all European countries. Synergy with the epidemiological network to collaboratively reach common goals is actively pursued to form one front. Web-based dashboard with highly secured information on performance and enhancement proposals are future perspectives. The mission of EURECCA is achieving and assuring high quality of multidisciplinary cancer management in Europe, accessible to all patients through the development and support of an international quality assurance structure, which is an audit structure, using anonymous patient data and compliant with national and international laws. EURECCA s goal is to enlarge the European platform and infrastructure to cooperate with national registries or audit structures, expand the coverage of cancer patient outcome data that is captured and audit the quality of multidisciplinary cancer care. Registration of outcome-based quality measurements will provide internal feed-back, benchmarking as well as transparency which will rapidly lead to improvements in cancer care. EURECCA s key activities in the next six year will focus on 1. Building a professional support structure 2. Increase EURECCA network and optimize ICT structure for data collection and processing, auditing 3. Development of cancer treatment guidelines, education and communication 4. Fundraising and income generation. Source: Six years plan to professionalize EURECCA, for more information please see the Strategic plan. 3 P age

4 EURECCA has an internationally recognized set of expertise to augment quality assurance in cancer care and access to expertise, and a large network all of value to stakeholders such as physicians, scientific societies, patient organizations, policy makers and pharma: Data collection, large database mining, study facilitation and processing of data. Analysis with SPSS, STATA, SAS, excel etc. Epidemiologists and statisticians who are specialized in this field of merging different data bases Defining uniform datasets Reporting to all contacts from cancer registries and/or national or regional audits. Writing manuscripts in collaborating with participants on the results of the analysis Organising international consensus conferences, symposia and meeting with the Board per tumour site group Education (development of e-learning multidisciplinary educational program/workshops), assisting in guideline formation and writing patient friendly summaries. Active patient involvement in improvement of cancer care Support multidisciplinary cancer care, integrated care pathways Organise international collaboration in pioneering treatments to improve cancer care and outcome analysis (such as non-surgical Wait&Watch after upfront CRT) Founder & President EURECCA Cornelis van de Velde C.J.H.van_de_Velde@lumc.nl CEO EURECCA Esther Bastiaannet E.Bastiaannet@lumc.nl General contact person EURECCA projects Renu Bahadoer R.R.Bahadoer@lumc.nl 4 P age

5 EURECCA Colorectal Contact persons Cornelis van de Velde Geerard Beets, chair Denise Hilling, International Watch & Wait database (IWWD) Maxime van der Valk, International Watch & Wait database (IWWD) Past projects European comparison of the following projects: Treatment and survival of colon cancer patients 80 years and older Treatment and survival of rectal cancer patients 80 years and older Adjuvant chemotherapy after rectal surgery with curative intent Adjuvant chemotherapy in colon cancer stage II E-learning CRC Present projects with project leaders Short-term mortality time trends 80+ Yvette Claassen, Renu Bahadoer, Esther Bastiaannet International Watch & Wait database Maxime van der Valk, Denise Hilling Detailed comparison chemotherapy stage III colon cancer Netherlands and Belgium Esther Bastiaannet, Johanneke Portielje Asymptomatic stage IV colorectal cancer, role of surgery (submitted) Anne Breugom Lateral lymph node treatment in rectal cancer, prospective multicenter study Miranda Future projects An online platform for collaboration between expert centres o Recommendations for selection and follow-up (consensus by Delphi) o Functional outcomes o Quality of life o Outcomes of patients with local excision Publications 1. Valentini V, Glimelius B, Minsky BD, Van Cutsem E, Bartelink H, Beets-Tan RG, et al. The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus. Radiother Oncol. 2005;76(3): Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol. 2009;92(2): P age

6 3. Valentini V, Coco C, Gambacorta MA, Barba MC, Meldolesi E. Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECA-CC2). Acta Chir Iugosl. 2010;57(3): Valentini V, Glimelius B. Rectal cancer radiotherapy: towards European consensus. Acta Oncol. 2010;49(8): van Gijn W, van de Velde CJ. Quality assurance through outcome registration in colorectal cancer: an ECCO initiative for Europe. Acta Chir Iugosl. 2010;57(3): van Gijn W, van de Velde CJ, members of the Ec. Improving quality of cancer care through surgical audit. Eur J Surg Oncol. 2010;36 Suppl 1:S van Gijn W, van de Velde CJ SSO John Wayne clinical research lecture: rectal cancer outcome improvements in Europe: population-based outcome registrations will conquer the world. Ann Surg Oncol. 2011;18(3): van Gijn W, van den Broek CB, Mroczkowski P, Dziki A, Romano G, Pavalkis D, et al. The EURECCA project: Data items scored by European colorectal cancer audit registries. Eur J Surg Oncol. 2012;38(6): van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, et al. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer. 2013;49(13): van den Broek CB, Boelens PG, Breugom AJ, van de Velde CJ. Improving thi Outcome of Colorectal Cancer: The EURECCA-Project. Colorectal cancer (2013) 2(4), van de Velde CJ, Boelens PG, et al. Experts Reviews of the Multidisciplinary Consensus conference Colon and Rectal Cancer Science, opinions and experiences from the experts of Surgery. Eur J Surg Oncol Apr;40(4): Boelens PG, Taylor C, Henning G, Marang-van de Mheen PJ, Espin E, Wiggers T, et al. Involving patients in a multidisciplinary European consensus process and in the development of a 'patient summary of the consensus document for colon and rectal cancer care'. Patient. 2014;7(3): Breugom AJ, Boelens PG, van den Broek CB, Cervantes A, Van Cutsem E, Schmoll HJ, et al. Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Ann Oncol. 2014;25(8): Quirke P, West NP, Nagtegaal ID. EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review. Virchows Arch. 2014;464(2): Tudyka V, Blomqvist L, Beets-Tan RG, Boelens PG, Valentini V, van de Velde CJ, et al. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol. 2014;40(4): P age

7 16. Valentini V, Glimelius B, Haustermans K, Marijnen CA, Rodel C, Gambacorta MA, et al. EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist's expert review. Radiother Oncol. 2014;110(1): van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50(1):1 e- e van den Broek CB, van Gijn W, Bastiaannet E, Moller B, Johansson R, Elferink MA, et al. Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands. Eur J Surg Oncol. 2014;40(12): Quality assurance in surgical oncology the EURECCA platform. Eur J Surg Oncol. 2014;40(11): Beets GL, Figueiredo NL, Habr-Gama A, van de Velde CJ. A new paradigm for rectal cancer: Organ preservation: Introducing the International Watch & Wait Database (IWWD). Eur J Surg Oncol. 2015;41(12): Breugom AJ, Bastiaannet E, Boelens PG, Iversen LH, Martling A, Johansson R, et al. Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. Eur J Cancer. 2016;63: Breugom AJ, Bastiaannet E, Boelens PG, Van Eycken E, Iversen LH, Martling A, et al. Oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania. Eur J Surg Oncol. 2018;44(9): Claassen YHM, Vermeer NCA, Iversen LH, van Eycken E, Guren MG, Mroczkowski P, et al. Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. Br J Cancer. 2018;119(4): Vermeer NCA, Claassen YHM, Derks MGM, Iversen LH, van Eycken E, Guren MG, et al. Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. Oncologist. 2018;23(8): P age

8 EURECCA Upper GI Contact persons William Allum, chair Renu Bahadoer Past projects International comparison of treatment strategy and survival in metastatic gastric cancer North European comparison of treatment strategy and survival in older patients with resectable gastric cancer International comparison of older patients with gastric cancer Comparison of treatment and survival of patients with metastasized gastric cancer Present projects with project leaders Comparison of treatment and survival in elderly patients with oesophageal cancer Renu Bahadoer Outcomes after a different treatment strategy for patients with potentially resectable oesophageal cancer UK vs NL Renu Bahadoer Publications 1. Dikken JL, van Sandick JW, Allum WH, Johansson J, Jensen LS, Putter H, et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg. 2013;100(1): de Steur WO, Henneman D, Allum WH, Dikken JL, van Sandick JW, Reynolds J, et al. Common data items in seven European oesophagogastric cancer surgery registries: towards a European upper GI cancer audit (EURECCA Upper GI). Eur J Surg Oncol. 2014;40(3): Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, et al. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev. 2014;40(6): Allum W, Osorio J. EURECCA oesophago-gastric cancer project. Cir Esp. 2016;94(5):255-6.(1) 5. Messager M, de Steur W, Boelens PG, Jensen LS, Mariette C, Reynolds JV, et al. Description and analysis of clinical pathways for oesophago-gastric adenocarcinoma, in 10 European countries (the EURECCA upper gastro intestinal group - European Registration of Cancer Care). Eur J Surg Oncol. 2016;42(9): Messager M, de Steur WO, van Sandick JW, Reynolds J, Pera M, Mariette C, et al. Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: A survey from the EURECCA Upper GI Group (EUropean REgistration of Cancer CAre). Eur J Surg Oncol. 2016;42(1): P age

9 7. Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, et al. North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis. Eur J Surg Oncol Osorio J, Jerico C, Miranda C, Garsot E, Luna A, Miro M, et al. Perioperative transfusion management in gastric cancer surgery: Analysis of the Spanish subset of the EURECCA oesophagogastric cancer registry. Cir Esp P age

10 EURECCA Pancreas Contact persons Sven Mieog Jesse Groen Past projects Common variables in European pancreatic cancer registries Differences in treatment and outcome of pancreatic adenocarcinoma stage I and II Present projects with project leaders Older patients with pancreatic cancer stage I & II Jesse Groen Future projects Focus on younger patients ( 40 years)? study protocol in progress by Jesse Groen Publications 1. de Leede EM, Sibinga Mulder BG, Bastiaannet E, Poston GJ, Sahora K, Van Eycken E, et al. Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project. Eur J Surg Oncol. 2016;42(9): Groen JV, Sibinga Mulder BG, van Eycken E, Valerianova Z, Borras JM, van der Geest LGM, et al. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. Ann Surg Oncol. 2018;25(12): P age

11 EURECCA Breast Contact persons Ricardo Audisio, chair Isabel Rubio Iris Noordhoek, INSPIRE Past projects Endocrine therapy patients with advanced breast cancer Treatment and survival of early breast cancer in older women Present projects with project leaders Primary metastatic breast cancer in older women Iris Noordhoek Nipple sparing mastectomy; INSPIRE trial Ricardo Audisio, Isabel Rubio, Iris Noordhoek Axillary treatment in Europe Sabrina, Nicole Future projects Focus on triple negative breast cancer Detailed comparison of 2 countries Publications 1. Kiderlen M, Ponti A, Tomatis M, Boelens PG, Bastiaannet E, Wilson R, et al. Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: a European Society of Breast Cancer Specialists database analysis. Eur J Cancer. 2015;51(10): Kiderlen M, Walsh PM, Bastiaannet E, Kelly MB, Audisio RA, Boelens PG, et al. Treatment strategies and survival of older breast cancer patients - an international comparison between the Netherlands and Ireland. PLoS One. 2015;10(2):e Kolacinska A. How Can We Improve Education of Breast Surgeons Across Europe? Chirurgia (Bucur). 2017;112(4):365-6.(2) 4. Derks MGM, Bastiaannet E, Kiderlen M, Hilling DE, Boelens PG, Walsh PM, et al. Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group. Br J Cancer. 2018;119(1): P age

12 EURECCA Melanoma Contact persons Ricardo Rossi, chair Esther Bastiaannet Past projects Identified shared variables: The EU-MELACARE study. Let by Antonio Sommariva and dr Carlo Riccardo Rossi (Padova, Italy) Future projects Comparison treatment and survival Differences in treatment strategy Stage- specific survival Publications 1. Sommariva A, Forsea AM, Agius D, Ascierto PA, Bastiaannet E, Borgognoni L, et al. Quality assurance in melanoma care: The EU-MELACARE study. Eur J Surg Oncol. 2018;44(11): P age